Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Demographics and clinical characteristics of the patients

From: Free thyroxine level is associated with both relapse rate and poor neurofunction in first-attack Neuromyelitis Optica Spectrum Disorder (NMOSD) patients

CharacteristicsLow-FT4 group (n = 54)High-FT4 group (n = 55)P value
Age -years41.21 ± 13.7843.18 ± 17.000.508
Male sex- no. (%)16 (29.63)11 (20.00)0.244
Hypertension - no. (%)3 (5.56)10 (18.18)0.042*
Diabetes - no. (%)0 (0.00)7 (12.73)0.007*
Initial EDSS5.03 ± 1.734.75 ± 1.870.415
Vision (EDSS of Vision)1.85 ± 2.101.56 ± 1.860.451
Optic neuritis - no. (%)13 (24.07)17 (30.91)0.559
Acute myelitis - no. (%)38 (70.37)35 (63.64)0.587
LESCL - no. (%)40 (74.07)42 (76.36)0.956
Anti-AQP-4 antibody - no. (%)  0.009*
 Not tested21 (38.89)9 (16.36) 
 Negative16 (29.63)14 (25.45) 
 Positive17 (31.48)32 (58.18) 
Autoimmune - no. (%)2 (3.70)3 (5.45)0.662
Corticosteroid - no. (%)48 (88.89)47 (85.45)0.592
IVIG - no. (%)2 (3.70)3 (5.45)0.662
Immunosuppressant - no. (%)16 (29.63)10 (18.18)0.161
Rehabilitation - no. (%)13 (24.07)10 (18.18)0.451
FT3 - pmol/L4.48 ± 0.664.61 ± 0.980.447
FT4 - pmol/L9.55 ± 1.4513.33 ± 1.78< 0.001*
TSH -μIU/mL4.75 ± 13.161.70 ± 1.330.090
Interval - days592.72 ± 423.23472.78 ± 364.310.116
Final EDSS1.37 ± 1.741.76 ± 1.790.249
Relapse - no. (%)17 (31.48)37 (67.27)< 0.001*
  1. no. Number, EDSS Expanded Disability Status Scale, LESCL Longitudinally extensive spinal cord lesions, IVIG Intravenous immunoglobulin, FT3 Free triiodothyronine, FT4 Free thyroxine, TSH Thyroid stimulating hormone
  2. *P < 0.05 indicates a significant difference between the two groups